Cargando…
Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928810/ https://www.ncbi.nlm.nih.gov/pubmed/36334173 http://dx.doi.org/10.1007/s11523-022-00928-4 |
| _version_ | 1784888720270295040 |
|---|---|
| author | Huang, Yen-Hsiang Hsu, Kuo-Hsuan Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Su, Kang-Yi Yu, Sung-Liang Chen, Jeremy J. W. Chang, Gee-Chen |
| author_facet | Huang, Yen-Hsiang Hsu, Kuo-Hsuan Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Su, Kang-Yi Yu, Sung-Liang Chen, Jeremy J. W. Chang, Gee-Chen |
| author_sort | Huang, Yen-Hsiang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9928810 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99288102023-02-16 Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan Huang, Yen-Hsiang Hsu, Kuo-Hsuan Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Su, Kang-Yi Yu, Sung-Liang Chen, Jeremy J. W. Chang, Gee-Chen Target Oncol Correction Springer International Publishing 2022-11-05 2023 /pmc/articles/PMC9928810/ /pubmed/36334173 http://dx.doi.org/10.1007/s11523-022-00928-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Huang, Yen-Hsiang Hsu, Kuo-Hsuan Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Su, Kang-Yi Yu, Sung-Liang Chen, Jeremy J. W. Chang, Gee-Chen Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan |
| title | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan |
| title_full | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan |
| title_fullStr | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan |
| title_full_unstemmed | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan |
| title_short | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan |
| title_sort | correction to: the difference in clinical outcomes between osimertinib and afatinib for first-line treatment in patients with advanced and recurrent egfr-mutant non-small cell lung cancer in taiwan |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928810/ https://www.ncbi.nlm.nih.gov/pubmed/36334173 http://dx.doi.org/10.1007/s11523-022-00928-4 |
| work_keys_str_mv | AT huangyenhsiang correctiontothedifferenceinclinicaloutcomesbetweenosimertinibandafatinibforfirstlinetreatmentinpatientswithadvancedandrecurrentegfrmutantnonsmallcelllungcancerintaiwan AT hsukuohsuan correctiontothedifferenceinclinicaloutcomesbetweenosimertinibandafatinibforfirstlinetreatmentinpatientswithadvancedandrecurrentegfrmutantnonsmallcelllungcancerintaiwan AT tsengjengsen correctiontothedifferenceinclinicaloutcomesbetweenosimertinibandafatinibforfirstlinetreatmentinpatientswithadvancedandrecurrentegfrmutantnonsmallcelllungcancerintaiwan AT yangtsungying correctiontothedifferenceinclinicaloutcomesbetweenosimertinibandafatinibforfirstlinetreatmentinpatientswithadvancedandrecurrentegfrmutantnonsmallcelllungcancerintaiwan AT chenkunchieh correctiontothedifferenceinclinicaloutcomesbetweenosimertinibandafatinibforfirstlinetreatmentinpatientswithadvancedandrecurrentegfrmutantnonsmallcelllungcancerintaiwan AT sukangyi correctiontothedifferenceinclinicaloutcomesbetweenosimertinibandafatinibforfirstlinetreatmentinpatientswithadvancedandrecurrentegfrmutantnonsmallcelllungcancerintaiwan AT yusungliang correctiontothedifferenceinclinicaloutcomesbetweenosimertinibandafatinibforfirstlinetreatmentinpatientswithadvancedandrecurrentegfrmutantnonsmallcelllungcancerintaiwan AT chenjeremyjw correctiontothedifferenceinclinicaloutcomesbetweenosimertinibandafatinibforfirstlinetreatmentinpatientswithadvancedandrecurrentegfrmutantnonsmallcelllungcancerintaiwan AT changgeechen correctiontothedifferenceinclinicaloutcomesbetweenosimertinibandafatinibforfirstlinetreatmentinpatientswithadvancedandrecurrentegfrmutantnonsmallcelllungcancerintaiwan |